Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498


Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention.

Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC.

Brain Commun. 2020;2(1):fcaa007. doi: 10.1093/braincomms/fcaa007. Epub 2020 Feb 6.


Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.

Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F.

J Prev Alzheimers Dis. 2019;6(4):228-231. doi: 10.14283/jpad.2019.37.


Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults.

Nosheny RL, Insel PS, Mattsson N, Tosun D, Buckley S, Truran D, Schuff N, Aisen PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Oct;82:110-119. doi: 10.1016/j.neurobiolaging.2019.07.005. Epub 2019 Jul 22.


Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study.

Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, Song B, Zhu SL, Li DH, Wang HF, Tan CC, Dong Q, Tan L, Mok V, Aisen PS, Weiner MM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Sep;15(9):1208-1217. doi: 10.1016/j.jalz.2019.05.006. Epub 2019 Aug 6.


Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.


The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease.

Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC.

Alzheimers Dement (N Y). 2019 Jul 18;5:308-318. doi: 10.1016/j.trci.2019.04.004. eCollection 2019.


Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]


Predicting the course of Alzheimer's progression.

Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC; Alzheimer’s Disease Neuroimaging Initiative.

Brain Inform. 2019 Jun 28;6(1):6. doi: 10.1186/s40708-019-0099-0.


Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.


Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.

Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21.


Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P.

J Prev Alzheimers Dis. 2019;6(3):164-168. doi: 10.14283/jpad.2019.12.


Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.

Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):157-163. doi: 10.14283/jpad.2019.14.


Editorial: Failure After Failure. What Next in AD Drug Development?

Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):150. doi: 10.14283/jpad.2019.23. No abstract available.


Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.

Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G.

N Engl J Med. 2019 Apr 11;380(15):1483-1485. doi: 10.1056/NEJMc1813435. No abstract available.


Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.


A randomized clinical trial to evaluate home-based assessment of people over 75 years old.

Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH; Alzheimer Disease Cooperative Study Investigators.

Alzheimers Dement. 2019 May;15(5):615-624. doi: 10.1016/j.jalz.2019.01.007. Epub 2019 Mar 11.


Unsuccessful trials of therapies for Alzheimer's disease.

Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC.

Lancet. 2019 Jan 5;393(10166):29. doi: 10.1016/S0140-6736(18)31896-8. No abstract available.


Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.

Rafii MS, Aisen PS.

CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1.


Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability.

Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG.

Neuroimage Clin. 2019;21:101574. doi: 10.1016/j.nicl.2018.10.012. Epub 2018 Oct 14.


Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative.

Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC.

Alzheimers Dement (Amst). 2018 Aug 29;10:657-668. doi: 10.1016/j.dadm.2018.07.008. eCollection 2018.


Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Review.


What We Learn from the CTAD (Clinical Trials Alzheimer's Disease) 2018.

Vellas B, Aisen P, Weiner M, Touchon J.

J Prev Alzheimers Dis. 2018;5(4):214-215. doi: 10.14283/jpad.2017.38. No abstract available.


Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial.

Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH.

Alzheimers Dement. 2018 Nov;14(11):1397-1405. doi: 10.1016/j.jalz.2018.05.016. Epub 2018 Oct 5.


Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S.

J Nutr Health Aging. 2018;22(8):982-998. doi: 10.1007/s12603-018-1052-2.


Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.

Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M; NILVAD Study Group.

PLoS Med. 2018 Sep 24;15(9):e1002660. doi: 10.1371/journal.pmed.1002660. eCollection 2018 Sep.


Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.


Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3.

Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen P.

J Prev Alzheimers Dis. 2018;5(3):184-187. doi: 10.14283/jpad.2018.22.


What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.


A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease.

Chen YF, Ni X, Fleisher AS, Zhou W, Aisen P, Mohs R.

Alzheimers Dement (N Y). 2018 Jan 18;4:46-53. doi: 10.1016/j.trci.2017.12.002. eCollection 2018.


Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Japanese Alzheimer's Disease Neuroimaging Initiative, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.


Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.


Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.

Cummings J, Fox N, Vellas B, Aisen P, Shan G.

J Prev Alzheimers Dis. 2018;5(2):103-109. doi: 10.14283/jpad.2018.13.


Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.

Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, Porsteinsson A, Rosenberg P, Schneider L, Touchon J, Aisen P, Vellas B, Lyketsos C.

J Prev Alzheimers Dis. 2018;5(2):98-102. doi: 10.14283/jjpad.2018.15.


Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.


Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.


Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Aisen PS.

Neurology. 2018 Jan 16;90(3):145. doi: 10.1212/WNL.0000000000004821. No abstract available.


Editorial: Collaborative Efforts to Prevent Alzheimer's Disease.

Touchon J, Rosenbaum J, Aisen P, Andrieu S, Carrillo MC, Ceccaldi M, Dartiques JF, Feldman H, Gabelle A, Isaac M, Fitten LJ, Sperling RA, Vellas B, Tariot P, Weiner M.

J Nutr Health Aging. 2017;21(10):1072-1074. doi: 10.1007/s12603-017-0961-9. No abstract available.


EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2017;4(2):116-124. doi: 10.14283/jpad.2017.13.


Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism.

Aisen PS.

J Prev Alzheimers Dis. 2017;4(4):211-212. doi: 10.14283/jpad.2017.34. No abstract available.


Elevated Brain Amyloid in Cognitively Normal Individuals-Reply.

Donohue MC, Aisen PS.

JAMA. 2017 Oct 10;318(14):1393-1394. doi: 10.1001/jama.2017.12962. No abstract available.


Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.

Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Lovestone S, Simmons A, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2017 Dec;60:92-103. doi: 10.1016/j.neurobiolaging.2017.08.010. Epub 2017 Aug 18.


The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Li C, Neugroschl J, Luo X, Zhu C, Aisen P, Ferris S, Sano M.

J Alzheimers Dis. 2017;60(2):427-437. doi: 10.3233/JAD-161294.


On the path to 2025: understanding the Alzheimer's disease continuum.

Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B.

Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.


Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report.

Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, Tosun D, Veitch DP, Jack CR Jr, Decarli C, Saykin AJ, Grafman J, Neylan TC; Department of Defense Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Jun;3(2):177-188. doi: 10.1016/j.trci.2017.02.005.


Cross-validation of optimized composites for preclinical Alzheimer's disease.

Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS; AN-ADNI; AIBL; J-ADNI.

Alzheimers Dement (N Y). 2017 Jan;3(1):123-129. doi: 10.1016/j.trci.2016.12.001.


Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2017 Jun 13;317(22):2305-2316. doi: 10.1001/jama.2017.6669.


Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Weiner MW, Green RC, Toga AW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

BMC Med Genomics. 2017 May 24;10(Suppl 1):29. doi: 10.1186/s12920-017-0267-0.


Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G.

J Prev Alzheimers Dis. 2016 Jun;3(2):114-120. doi: 10.14283/jpad.2016.93. Epub 2016 Mar 4.


Statistical properties of continuous composite scales and implications for drug development.

Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, Siemers E.

J Biopharm Stat. 2017;27(6):1104-1114. doi: 10.1080/10543406.2017.1315819. Epub 2017 Apr 27.


Randomized controlled trials in mild cognitive impairment: Sources of variability.

Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team.

Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5.

Supplemental Content

Support Center